Knowledge base
How our evidence grades work
We grade the strength of the evidence behind each peptide honestly, strongest first. For most non-GLP-1 peptides the evidence is thin, and we say so rather than dress it up.
Randomised controlled trials in humans — the strongest routine evidence. Reserved for peptides with genuine trial programmes (mostly the GLP-1 medicines and a few approved agents).
Human data without randomisation — cohort studies, case series, or regional clinical use. Suggestive but more prone to bias.
Evidence from animal models or laboratory studies only. Frequently does not translate to humans. Much peptide enthusiasm rests here.
Self-reports, forums and vendor claims. Not evidence of efficacy or safety. Treat with the most scepticism.
A high grade means the evidence is strong, not that a peptide is safe or legal for you. Legal status varies by country and changes over time; always verify locally and consult a licensed clinician.